Chargement en cours...

ABCG2 Deficiency Does Not Alter Dolutegravir Metabolism and Pharmacokinetics

Dolutegravir (DTG) is a potent integrase inhibitor of human immunodeficiency virus. Because DTG is a substrate of the efflux transporter ABCG2 and ABCG2 is highly polymorphic, we asked whether dose adjustment of DTG is needed for ABCG2-deficient individuals. Using Abcg2-null mice, the current work i...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Pharmacol Exp Ther
Auteurs principaux: Zhu, Junjie, Tian, Xin, Shehu, Amina I., McMahon, Deborah K., Ma, Xiaochao
Format: Artigo
Langue:Inglês
Publié: The American Society for Pharmacology and Experimental Therapeutics 2020
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7292963/
https://ncbi.nlm.nih.gov/pubmed/32303561
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.119.264424
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!